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Background: The Strategic Advisory Group of Experts (SAGE) Working Group on rabies vaccines and
immunoglobulins was established in 2016 to develop practical and feasible recommendations for preven-
tion of human rabies. To support the SAGE agenda we developed models to compare the relative costs
and potential benefits of rabies prevention strategies.
Methods: We examined Post-Exposure Prophylaxis (PEP) regimens, protocols for administration of Rabies
Immunoglobulin (RIG) and inclusion of rabies Pre-Exposure Prophylaxis (PrEP) within the Expanded
Programme on Immunization (EPI). For different PEP regimens, clinic throughputs and consumables
for vaccine administration, we evaluated the cost per patient treated, costs to patients and potential to
treat more patients given limited vaccine availability.
Results: We found that intradermal (ID) vaccination reduces the volume of vaccine used in all settings, is
less costly and has potential to mitigate vaccine shortages. Specifically, the abridged 1-week 2-site ID reg-
imen was the most cost-effective PEP regimen, even in settings with low numbers of bite patients pre-
senting to clinics. We found advantages of administering RIG to the wound(s) only, using considerably
less product than when the remaining dose is injected intramuscularly distant to the wound(s). We found
that PrEP as part of the EPI programme would be substantially more expensive than use of PEP and dog
vaccination in prevention of human rabies.
Conclusions: These modeling insights inform WHO recommendations for use of human rabies vaccines
and biologicals. Specifically, the 1-week 2-site ID regimen is recommended as it is less costly and treats
many more patients when vaccine is in short supply. If available, RIG should be administered at the
wound only. PrEP is highly unlikely to be an efficient use of resources and should therefore only be con-
sidered in extreme circumstances, where the incidence of rabies exposures is extremely high.
 2019 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Background
Considerable efforts are underway to reduce the burden of
rabies, with the goal of reaching zero human deaths due to dog-
mediated rabies by 2030 [1]. The main strategies to prevent human
rabies are (1) canine vaccination to eliminate rabies at its source
and (2) Post-Exposure Prophylaxis (PEP) comprising wound wash-ing, vaccination and, when indicated, Rabies Immunoglobulin
(RIG), to individuals bitten by suspect rabid animals [2]. An addi-
tional preventive strategy is Pre-Exposure Prophylaxis (PrEP)
whereby vaccine is given to prime the immune system [3]. Individ-
uals who have received rabies PrEP still require PEP, but need
fewer (booster) doses than unprimed individuals and do not
require RIG. To support the development of practical and feasible
recommendations for human rabies prevention WHO established
a Strategic Advisory Group of Experts (SAGE) Working Group on
rabies vaccines and immunoglobulins in 2016 (http://www.who.
int/immunization/policy/sage/sage_wg_rabies_jul2016/en/). As
part of this process, we compared PEP regimens, approaches to
RIG administration and PrEP to assess their relative merits.
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individuals and several regimens have been recommended [4].
Intradermal (ID) regimens are more cost-effective than intramus-
cular (IM) regimens [5], because smaller volumes of vaccine are
used to elicit a clinically equivalent immune response. So far only
a few countries have adopted ID vaccination, with several factors
likely contributing. Fractionated vials should be discarded within
6–8 h to minimize risks of bacterial contamination (rabies vaccines
do not contain preservatives) [4,6], which is often perceived as
waste [1]. Inexperienced clinicians may consider ID vaccination
to require more skill, and fear that smaller doses are less protec-
tive. Rabies vaccine is available as 0.5 mL or 1 mL vials. Using stan-
dard syringes with mounted needles, clinicians usually obtain four
ID doses of 0.1 mL from 0.5 mL vials and 8 from 1 mL vials, with
wastage of 20%. Use of more expensive insulin syringes with
built-in needles and no dead space prevents such wastage and
the same needle can be used to withdraw vaccine and inject the
patient.
RIG is recommended for severe exposures to potentially rabid
animals and all bat exposures, providing passive immunity while
the vaccine elicits an active immune response [7]. The previous
WHO recommendation calculates dosage according to patient
body weight, with as much RIG as is anatomically possible being
administered into and around the wound(s) and the remaining
product being injected intramuscularly distant from the wound
[4]. New evidence led to revised protocols for administering RIG
at the wound only [8,9]. RIG vials can be shared between patients
using single-use injection devices, but opened vials should also be
discarded at the end of each day.
A systematic review on safety, immunogenicity, cost-
effectiveness and recommendations for use of rabies PrEP con-
cluded that PrEP ‘‘is safe and immunogenic and should be
considered: (i) where access to PEP is limited or delayed; (ii) where
the risk of exposure is high and may go unrecognized; and (iii)
where controlling rabies in the animal reservoir is difficult” [3].
Rabies PrEP programmes have been implemented in Peru (for
exposures via vampire bats) and the Philippines (targeting children
at risk of dog-transmitted rabies) [3]. Offering widespread PrEP, for
example within routine EPI programmes in rabies-endemic
countries, raises practical and operational difficulties, as delivering
multiple doses within short time scales (i.e. 1-week) lies outside
the standard programme. However, if PrEP could be a cost-
effective method to prevent human rabies, ways to overcome these
challenges should be considered.
We developed models to quantitatively assess the potential
benefits and costs of these strategies for prevention of dog-
mediated rabies.Table 1
Rabies post-exposure vaccination regimens investigated and costs to patients under differe
[23] were not examined as these were previously replaced by the 2-week IM and 1-month
by the SAGE working group and deemed ± safe, but not WHO-approved/selected due to cost
indirect costs assuming low travel costs ($2.5/clinic visit) for patients who live close to a clin
with reduced numbers of patient visits to clinics have lower indirect costs, therefore redu
Regimen Route Visits Schedule
(days)
Injecti
2-Week IM (4-dose Essen) [24] IM 4 0, 3, 7, 14 1, 1, 1
3-Week IM (Zagreb) [25,26] IM 3 0, 7, 21 2, 1, 1
1-Month 2-site ID (Updated TRC) [27] ID 4 0, 3, 7, 28 2, 2, 2
1-Week 2-site ID [28] ID 3 0, 3, 7 2, 2, 2
1-Week 4-site ID [29–31] 3 0, 3, 7 4, 4, 4
1-Month simplified 4-site ID [32] ID 3 0, 7, 28 4, 2, 1
* Calculated assuming use of 0.5 mL vials.2. Methods
2.1. PEP regimens
We updated a simulation to compare PEP regimens [5] (Table 1).
Briefly, our algorithm involved: (1) assigning patient presentation
dates uniformly based on clinic throughput; (2) generating patient
return dates based on specified regimens and patient compliance;
(3) calculating daily vial use; (4) iterating steps 1–3 to capture
variation.
Direct (medical) costs for vaccines and their administration
and indirect (non-medical) costs (including transport to/from
clinics) were taken from published data and expert consultation
(Table 2). We assumed that vaccine administration time is equiv-
alent for all regimens. For this analysis we did not include RIG
because it is rarely available to bite victims in endemic countries
[10–14].
We explored vial use according to:
Clinic throughput: monthly numbers of bite patients presenting
to clinics to initiate PEP. Total presentations depend on the reg-
imen, its schedule requirements (Table 1), clinic accessibility
[15] and patient compliance.
Vial size:most rabies vaccines are sold in 0.5 mL or 1 mL vials, at
equal cost. Vial size affects numbers of doses that can be with-
drawn, as does syringe type.
Vaccine wastage: vaccine from opened vials must be used within
6–8 h or discarded. We assumed use of WHO pre-qualified
rabies vaccines, with 0.1 mL doses for all regimens.
Syringe type: We compared costs of using insulin syringes that
reduce waste compared to standard syringes (20% wastage).
For all regimens we assumed use of an additional syringe per
vial to reconstitute the vaccine.
Patient compliance: the probability of a bite patient completing
PEP vaccination(s). Whatever its cause, poor compliance has
consequences for vaccine use, vial sharing and PEP efficacy.
We did not consider variability in return dates.
We ran 1000 realisations for each scenario to capture variation
in patient presentation dates and vial sharing. We compared costs
for bite victims depending upon pricing strategies and indirect
costs (Table 2). We assume bite victims travel further to reach rural
clinics compared to urban clinics and incur correspondingly higher
costs, spanning the range from $2.5 to $15 per clinic visit [16]. To
investigate limited vaccine supply we assessed the maximum
number of patients that could be treated with a given volume of
vaccine under different regimens.nt pricing strategies and travel costs. The 5-visit Essen [22] and 5-visit TRC regimens
2-site ID regimens respectively [2]. Regimens included in the analysis were reviewed
-effectiveness, feasibility or limited availability of clinical outcome data. We compared
ic and high travel costs ($15/clinic visit) for those who live far from a clinic. Regimens
cing visits should be prioritized for future regimens.
ons Vials Vol
(mL)*
Travel $2.5 ID dose/
$10 vial
$15 PEP/$10
vial
Near Far Near Far Near Far
, 1 4 4(2*) 10 60 50 100 50 100
4 4(2*) 7.5 45 47.5 85 47.5 85
, 2 4 0.8 10 60 30 80 25 75
3 0.6 7.5 45 22.5 60 22.5 60
3 1.2–1.5 7.5 45 37.5 75 22.5 60
3 0.7 7.5 45 25 62.5 22.5 60
Table 2
Costs for calculating the cost-effectiveness of post-exposure vaccination regimens per patient treated. Costs in bold were used as the default in simulations. Insulin syringes/
needles were compared to standard 1CC syringes for ID regimens only. Non-medical costs were only considered when examining costs to patients.
Cost Parameter Unit cost estimate (USD) Details
Medical Material costs per injection (needles, syringes) $0.033–0.4 Standard syringe  2/consultation for ID regimens,
1/consultation for IM
0.1455 Insulin needle  1/consultation
Overhead per clinic visit (staff salaries
& administration)
$0.5–1.2 Depends on country/setting
Vaccine costs per vial $6.6–20 ($10) Depends on country/setting
Non-medical Transport and accommodation costs per clinic visit $2–15 Depends on country/setting
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We undertook a similar analysis for RIG using data collected
over 12-months from Himachal Pradesh, India. Due to limited
RIG availability, patients (N = 700, median age: 30 years, median
weight: 53 kg, sex ratio: 63:37 male:female) were administered
RIG under a dose-sparing approach of infiltration of the wound
only. All survived on follow-up [8,9]. We used bootstrap sampling
of these data, where patient weight was measured, to capture vari-
ability in RIG use under two scenarios: (1) infiltration at the wound
(s) with the remainder administered intramuscularly distant from
the wound; and (2) infiltration of the wound(s) only. We assumed
opened RIG vials were discarded at the end of each day and exam-
ined a range of clinic throughputs using 5 mL ERIG vials containing
not less than 300 IU/mL, as available in Himachal Pradesh.
2.3. PrEP
We took two approaches to quantify the potential benefits and
relative costs of including rabies PrEP within a routine EPI schedule
in endemic settings:
a. Hypothetical birth cohort
We developed a simple simulation model to estimate the rela-
tive cost of PrEP plus PEP versus PEP alone. This cost ratio largely
depends on the incidence of dog bites (for which individuals seek
PEP) and the cost per course of PrEP plus PEP vs PEP alone.
Bite incidence: The incidence of dog bites in endemic settings
has been reported to vary from around 12 per 100,000 population
(Chad) to around 1200 per 100,000 population (India, Sri Lanka,
Cambodia, Myanmar) [17]. A more recent systematic review cover-
ing 2013–2015 reported typical bite incidence in the range 10–130
per 100,000 per year (WHO, unpublished). The highest reported
bite incidence we identified in the literature is 4840 per 100,000
in rural Cambodia which is far higher than reported in any other
setting [18]. Since PEP costs are only relevant for individuals who
seek care, crude bite incidence should be modified by the propor-
tion of people seeking care. We modelled a typical range of care-
seeking bite victims of 10–500 per 100,000 population per year.
Costs of PrEP and PEP: We did not model all regimens considered
for PEP and PrEP individually, assuming any differences in rabies
prevention would be marginal. We assumed costs of PEP for those
who have been primed to be the same as for PrEP, but this does not
fully capture the variation in all of the recommended regimens.
Although it is the relative rather than absolute costs that are
important, for simplicity we assumed that dose-sparing regimens
would be used giving PrEP costs of between $5 and $20 and PEP
costs in naïve individuals of $10–160, with the upper end of this
range high enough to include RIG provision. We did not consider
tetanus vaccination which is often given alongside PEP.
Simulation. Assuming that both bite incidence and costs of PrEP
and PEP followed a uniform distribution we ran 10,000 simulations
to estimate the ratio of costs for a hypothetical cohort of 100,000children with high EPI vaccine uptake. We assumed protection
from PrEP lasted for 20 years as an optimistic assumption based
on limited data [3] and that dog bites are most common in chil-
dren. Future costs were not discounted.
b. N’Djamena, Chad
A model was previously developed to estimate the cost-
effectiveness of PEP alone to prevent human rabies deaths versus
PEP plus dog vaccination for N’Djaména, Chad [14]. To evaluate
the cost-effectiveness of PrEP in the same setting, we compared a
scenario incorporating PrEP vaccination of a yearly cohort of chil-
dren with these published scenarios. For all scenarios we assumed
maximum access to PEP and that communication between the vet-
erinary and human health sector guided treatment.
The number of suspected rabies exposures were taken from
data collected in 2012 in approximately 30% of all health facilities
in N’Djaména, including all public health centres and hospitals,
prior to a mass dog vaccination campaign [19]. Suspicion was
defined based on the animal status and was attributed to bites
from unvaccinated animals and animals that died, vanished, or
were killed without laboratory diagnosis within 10 days of the bite.
The Essen 5-dose IM regimen is used in N’Djaména with PEP cost-
ing 198 USD including transport and personnel, but not RIG, which
is unavailable in Chad. We considered PrEP costs of 83 USD cover-
ing 3 vaccine doses, transport, loss of work time and personnel for
administration. We assumed that pre-vaccinated children require
2 additional vaccine doses if exposed, amounting to 66.5 USD.
We assumed PrEP coverage of 55% based on observed ’measles
1’ vaccination coverage in Chad [20]. This is probably optimistic as
a full rabies PrEP schedule requires 2 visits [4] rather than just 1 for
measles. To achieve this coverage, approximately 57,270 children
must be vaccinated annually in N’Djaména. We simulated the change
of PrEP coverage in children under 15 years over a 20-year period
using a demographic model with data from the 2009 national census.
Multiplying this coverage by the percentage of children among
exposure victims generated an increasing number of children requiring
two PEP doses instead of 5. The overall cost of this scenario is the sum of
costs for PrEP, PEP for pre-vaccinated children and PEP for unvac-
cinated children and adults. Cumulative costs were discounted at
a rate of 0.04 [8] and DALYs averted were based on a 19% risk of
developing rabies after exposure by a suspect rabid animal [21].
Analyses were conducted using R version 3.4.1 except for the
N’Djamena demographic model which was conducted in vensim.
Code and data for reproducing the PEP and RIG simulations
are available at: https://github.com/katiehampson1978/Modelling_
rabies_regimens
3. Results
3.1. PEP regimens
Overall, ID vaccination is always more cost-effective than IM
vaccination, is less costly for health providers and either costs less
K. Hampson et al. / Vaccine 37 (2019) A166–A173 A169or equivalent for patients (Fig. 1, Table 1). The cost-effectiveness of
IM vaccination does not change with clinic throughput. For ID vac-
cination cost-effectiveness increased with throughput (and if
reconstituted vaccine could be stored for longer than 8 h cost-
effectiveness would further increase at lower throughputs). The
1-week 2-site ID regimen is the most cost-effective regimen in
all settings because less vials are used per course than for IM vac-
cination (4 vs 3 with 1 mL vials), even without vial sharing. The
requirement for patients to return to clinics for subsequent doses
means opportunities for vial sharing occur even in low throughput
settings (Figs. 2 and S1). In high-throughput clinics the 1-week
2-site ID regimen uses 85% fewer 1 mL vials than IM regimens
(Fig. 1). Use of insulin syringes rather than standard syringes with
mounted needles further reduced costs, particularly in clinicsD
ire
ct
 m
ed
ica
l c
os
ts
 p
er
 p
at
ie
nt
 tr
ea
te
d 
(U
SD
)
0
10
20
30
40
1 2 5 10 20 50 200 500
0.5mL vials
IM
Updated TRC
1−week 4−site
    1−month 
 simplified 4−site
1−week 2−site
A
Monthly clinic through
0
10
20
30
40
1 2 5 10 20
1m
B
250 vials available
Pa
tie
nt
s 
tre
at
ed
0
20
0
40
0
60
0
80
0
10
00
IM
 
Up
da
ted
 T
RC
 
1−
we
ek
 4
−s
ite
 ID
sim
pli
fie
d 4
−s
ite
 ID
1−
we
ek
 2
−s
ite
 ID
 
D 1000 vials
0
20
0
40
0
60
0
80
0
10
00
IM
 
Up
da
ted
 T
RC
 
1−
we
ek
 4
−s
ite
 I
s
E
Fig. 1. Comparison showing that ID PEP regimens are more cost-effective per patient trea
direct medical costs per patient treated are shown in relation to clinic throughput, vial
black line) and do not change with clinic throughput whereas the cost of ID regimens imp
use injection devices - with greater savings for equivalently priced 1 mL vs 0.5 mL vials,
week 2-site ID regimen, is shown in panel C comparing insulin versus standard syringes.
over a 1-year period. Note the different y-axis limits for panel F.receiving >10 new bite patients each month (Fig. 1). The same
qualitative patterns were observed with lower patient compliance,
therefore these results are not presented.
ID regimens are dose-sparing and have greater potential to treat
more patients given limited vaccine supply (Fig. 1). The 1-week 2-
site ID regimen can treat 5 times as many patients than IM regi-
mens given an annual supply of 3000 vials (>70 new patients per
month).
Where PEP is provided free-of-charge, the 3-week IM and 1-
week ID regimens are preferable for patients, who incur only indi-
rect costs, as both require just 3 clinic visits (Table 1). When
patients must pay for PEP, the most preferable regimen depends
on pricing strategies and relative travel costs, but ID regimens
are always preferable to IM.put (new bite patients)
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ted and able to treat more patients given limited vaccine availability. In panels (A–C)
size and syringe type. The cost of both approved IM regimens are equivalent (solid
roves with patient throughput as vials can be shared between patients using single-
especially in high-throughput clinics. Only the most cost-effective regimen, the 1-
In panels (D–F) we assumed clinics only had only 250, 1000 or 3500 vials available
Fig. 2. Example patient presentation dates in a low throughput clinic with an
average of 5 new patients presenting monthly. Red bars show dates patients
initiated PEP and pink bars correspond to subsequent return dates following the 1-
week 2-site ID regimen. In this example 140 vials are used with vials shared on days
with 2 or more patient presentations. In this situation because of vial sharing 20%
fewer vials are used than if no vials were shared. (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version of
this article.)
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Infiltration of RIG at the wound(s) only results in considerable
savings, that increase with patient throughput as vials can be more
effectively shared between patients using single-use injection
devices (Fig. 3). Moreover, when available vials are limited, many
more patients can be treated if RIG is only administered at the
wound site(s). In the clinic in Himachal Pradesh, around 270
patients are seen per month requiring approximately 262 RIG vials
if injected at the wound only, versus 370 vials if the remainder is
administered distant to the wound, a 40% reduction.3.3. PrEP in the routine EPI schedule
a. Hypothetical birth cohort
Use of PrEP plus PEP boosters was at least twice as expensive as
PEP alone in 75% of simulations. In some simulations where bite
incidence was low and PEP costs in naïve individuals were also rel-
atively low, the ratio was in the range of 100–200. In 4% of simu-
lations (Fig. 4, black points) the ratio was 1, meaning that PrEPFig. 3. Comparison of patients treated with RIG when infiltrated at the wound with the
infiltrated to the wound(s) only (red). (A) Vials used under different patient throughputs a
vials and 5000 vials per year.plus PEP was less expensive than PEP alone; here both bite inci-
dence and relative PEP costs in naïve individuals were very high.
b. N’Djamena, Chad
The annual number of suspect rabies exposures for N’Djamena
based on reported bite patients was 374, of which 42% were chil-
dren [14]. This is a conservative estimate, since the survey did
not cover all pharmacies and private medical facilities. We esti-
mate that after 20 years the cumulative cost of PrEP plus PEP
was over fifty times higher than the cumulative cost of PEP alone
and PEP with mass dog vaccination (Fig. 4). The cost per DALY
averted is $3242 USD versus just $43 USD using only PEP. In prac-
tice, 100% access to PEP is impossible to achieve, but even when
compared to observed PEP use in N’Djamena [14], which prevents
rabies at a cost of 171 USD per DALY averted, PrEP remains much
less cost-effective. PrEP coverage among children stabilizes at
around 35% after 35 years, whereas coverage in adults stabilizes
at 35% only after 40 years.4. Discussion
The models we developed provide evidence to support practical
and feasible recommendations for human rabies prevention in dif-
ferent clinical settings. The safety and efficacy of ID administration
of rabies PEP has been recognized for decades [33]. New data sup-
ports the clinical efficacy of an abridged ID regimen [28,34], and
confirms that ID vaccination can be safely completed within one
week [35]. Our results further establish that ID vaccination could
considerably reduce vial use, mitigate shortages and provide more
equitable access by making PEP more affordable. Specifically, the
1-week 2-site ID regimen was the most cost-effective regimen,
with further advantages of enabling PEP to be completed within
1 week, requiring only 3 clinic visits and treating more patients
when vaccine is in short supply. We found similar advantages of
RIG administration to the wound(s) only, an advantage that is
more pronounced in higher throughput clinics. We found that PrEP
would be substantially more expensive than other measures to
prevent human rabies deaths, such as PEP and mass dog vaccina-
tion in almost all settings.
Clinic throughput affects capacity for vial sharing, and therefore
the cost-effectiveness of ID versus IM vaccination. But, ID regimensremainder administered intramuscularly distant from the wound (blue) and when
nd (B) patients treated given limited vial availability with examples shown for 1000
Fig. 4. Comparison of the costs of rabies prevention using PrEP plus PEP versus PEP or in combination with dog vaccination. In (A) the costs of PrEP plus PEP versus PEP alone
is shown in relation to dog bite incidence in a generic cohort model and in (B) extrapolated cumulative costs of PrEP plus PEP, PEP alone, and PEP and dog vaccination are
shown for N’Djamena, Chad. In (A) simulations with a final cost ratio 1 are indicated in black.
K. Hampson et al. / Vaccine 37 (2019) A166–A173 A171always use at least 25% fewer vials than IM, and as throughput
increases, ID regimens become increasingly cost-effective, using
up to 85% fewer vials. ID vaccination is safe, well-tolerated and
clinically efficacious [4]. Health workers routinely deliver BCG
immunizations intradermally [36], so there should be no technical
difficulty in switching to ID administration. Use of insulin syringes
should further reassure clinicians and reduce wastage as more
accurate vaccine volumes can be injected (Fig. S1). Single-use pre-
filled injection devices could eliminate vaccine waste and would be
more user-friendly therefore should be considered for future
development if costs can be kept low. Similarly, research into vac-
cine preservation could enable more economical vaccine use [37].
However, most critically, only two human rabies vaccines are cur-
rently WHO prequalified [2]. Prequalification is an important step
to accelerate widespread adoption of the new abridged 1-week 2-
site ID regimen and should be encouraged.Our model has several simplifications: we assume that the day
of the week does not affect the likelihood of presenting for PEP. But
patients may be less likely to present on Sundays (when clinics are
often closed) and/or more likely to present on Mondays or other
days (e.g. after pay day), which may affect vial sharing. We also
only consider a range of travel costs to clinics but in practice the
location of clinics and transport access would affect indirect costs
and delays to PEP provision. Moreover, we do not consider cluster-
ing of presentations as frequently occurs due to the same dog bit-
ing multiple people [38–41], which increases opportunities for vial
sharing. Finally, an opened vial may be additionally used for PrEP
in non-bitten family members or individuals whose occupation
increases their risk of exposure.
We also find major advantages of RIG administration to the
wound site(s) only. This allows many more patients to be treated
given limited RIG availability, an advantage that is more pro-
A172 K. Hampson et al. / Vaccine 37 (2019) A166–A173nounced in high throughput settings (Fig. 3). This analysis assumes
patients comparable to those from Himachal Pradesh in terms of
body weight and wounds. Preservatives could enable opened RIG
vials to be safely stored at 2–8 C for up to 28 days increasing vial
sharing opportunities, which should be further investigated.
Our results showed that mass pre-exposure vaccination for
rabies is unlikely to be an efficient use of scarce resources. We
assume PEP will always be necessary after exposure to a poten-
tially rabid animal, therefore there are limited health benefits
and substantial costs associated with PrEP. Use of PrEP in the EPI
schedule targets many more children than are likely to be exposed
to rabies and unlike most other infectious diseases, this risk is
identifiable (i.e. bite victims can be targeted for PEP [40,41]). Of
course, this assumes that PEP is available, which may not always
be the case. However, in view of vaccine shortages observed in
some countries, diverting vaccine from PEP to PrEP could be fatal
for exposed victims and marginalized communities that already
have limited PEP access and would likely also have limited PrEP
access, compounding health inequalities. Any country seriously
considering routine PrEP should assess relative effectiveness and
cost-effectiveness of this approach compared to other measures,
using models informed by local epidemiology.
We used two modelling approaches, one generic and one
context-specific, to address the potential costs and cost-
effectiveness of PrEP. For the hypothetical birth cohort we simu-
lated a range of bite incidence and relative costs. We did not take
into account differential immunogenicity as all regimens are
expected to be clinically equivalent, nor did we account for age-
specific variation in dog bites. In the specific example, parameters
were based upon extensive field studies. We did not model PrEP
use in other settings but there are additional studies reported in
the literature (summarised in [3]). One from Thailand similarly
found that bite incidence would need to be much higher than
has been observed to make PrEP cost-comparable [42].
These analyses suggest that investing in PEP, and/or mass dog
vaccination, will be preferable to PrEP. Our findings are in agree-
ment with the recent systematic review of PrEP [3]. Even if the
price of rabies vaccine were considerably lower, the marginal
cost-effectiveness of PrEP is still likely to be less favourable than
PEP or dog vaccination, simply because many more individuals
need to be targeted.5. Conclusions
Overall, we find that ID is more economical than IM vaccination.
The 1-week 2-site ID regimen is the most cost-effective and could
enable many more bite victims to be equitably treated with the
same volume of vaccine. We recommend use of insulin syringes
(Fig. S1) to efficiently administer ID vaccination and reassure
clinicians. Moreover, we encourage further efforts to prequalify
rabies vaccines to accelerate adoption of ID vaccination. Where
RIG is available, it could be delivered to most patients by infiltra-
tion at the wound only. We find that PrEP as part of the EPI
programme is highly unlikely to be an efficient use of resources
and should only be considered in extreme circumstances, where
incidence of rabies exposures is high in populations which cannot
access timely PEP. Modelling could be used to support decision
making in specific high-exposure contexts.Conflict of interest statement
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